Malignant tumors in young patients present a significant therapeutic challenge for physicians, partially due to their rarity and a relative lack of data, at least compared to adult tumors. As a result, there is an urgent need to explore new possible therapeutic regimens, either by introducing novel agents or by exploring combinations of existing agents. Vincristine, Temozolomide and Irinotecan are chemotherapeutic drugs which have emerged over the last six decades as monotherapy or as part of therapeutic regimens in various solid tumors. Combining these agents can yield strong synergistic effects, as suggested by preclinical data and results from clinical trials. Furthermore, adding novel molecules, such as anti-VEGF factor Bevacizumab to the aforementioned regimens, has shown efficacy in a limited number of trials, which are thoroughly analyzed throughout this review. Data presented throughout this paper suggest that VIT(b) regimen should be further explored in solid tumors in pediatric and adolescent patients.

年轻患者的恶性肿瘤对医生来说是一个重大的治疗挑战，部分原因是它们的罕见性和相对缺乏数据，至少与成人肿瘤相比。因此，迫切需要通过引入新的药物或探索现有药物的组合来探索新的可能的治疗方案。长春新碱、替莫唑胺和伊立替康是过去六十年来作为单一疗法或作为各种实体瘤治疗方案的一部分出现的化学治疗药物。正如临床前数据和临床试验结果所表明的那样，将这些药物结合起来可以产生强大的协同作用。此外，在上述方案中添加新分子，如抗 VEGF 因子贝伐珠单抗，已在有限数量的试验中显示出疗效，在本次审查中对其进行了彻底分析。本文中提供的数据表明，应在儿童和青少年患者的实体瘤中进一步探索 VIT(b) 方案。